| Catalog No. | VK515016 |
|---|
| Description | Diridavumab, the alternative name, CR6261, is a human monoclonal antibody directed against influenza A hemagglutinin. The CR6261 antibody was first discovered by the Scripps Institute and Crucell, a Dutch biopharmaceutical company, and later developed by Janssen Pharmaceutical Companies of Johnson & Johnson under the trade name diridavumab. Cr6261 is under investigation in clinical trial NCT02016066 (A Study to Assess the Safety, Pharmacokinetics and Immunogenicity of Diridavumab in Japanese Healthy Participants). |
|---|
| Species reactivity | InfluenzaAvirus |
|---|
| Applications | Research Grade Biosimilar |
|---|
| Host species | Human |
|---|
| Isotype | IgG1, lambda |
|---|
| Expression system | Mammalian Cells |
|---|
| Clonality | Monoclonal |
|---|
| Target | HA/Hemagglutinin |
|---|
| Concentration | 1.41mg/ml |
|---|
| Endotoxin level | Please contact the lab for this information. |
|---|
| Purity | >95% purity as determined by SDS-PAGE. |
|---|
| Purification | Protein A/G, purified from cell culture supernatant. |
|---|
| Accession | P03455 |
|---|
| Form | Liquid |
|---|
| Storage buffer | 0.01M PBS,pH7.4. |
|---|
| Stability and Storage | Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -484°C. |
|---|
| Alternate Names | CR-6261,CR6261,CAS:1393659-46-5 |
|---|
| Background | Diridavumab is a monoclonal anti-HA stalk antibody. Diridavumab stabilizes the prefusion HA structure and prevents pH-dependent fusion of cellular and viral membranes in endosomes. Diridavumab can be used in research of H2 influenza virus. |
|---|
| Note | For research use only. Not for use in clinical or therapeutic applications. |
|---|
